Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AstroStem-V in COVID-19 Pneumonia
NCT04527224Phase 2Unknown
- Sponsor
- NatureCell
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AstroStem-V in COVID-19 pneumonia, sponsored by NatureCell. Primary endpoints: Incidence of adverse events and Abnormalities of physical examination, vital signs, and laboratory test. Status: unknown.
02
Drugs
AstroStem-V
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04527224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527224.